Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
Zhao Y, Mei T, Na F, Tian X, Ao R, Long X, Luo Q, Duan P, Zhu J, Wang Y, Huang M, Liu Y, Gong Y. Zhao Y, et al. Among authors: na f. Invest New Drugs. 2024 Apr;42(2):196-206. doi: 10.1007/s10637-024-01424-4. Epub 2024 Feb 22. Invest New Drugs. 2024. PMID: 38386170 Free PMC article.
Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival.
Chen X, Zhang Y, Zhou X, Wang M, Na F, Zhou L, Xu Y, Zou B, Xue J, Liu Y, Gong Y. Chen X, et al. Among authors: na f. Front Oncol. 2023 Oct 10;13:1274924. doi: 10.3389/fonc.2023.1274924. eCollection 2023. Front Oncol. 2023. PMID: 37886166 Free PMC article.
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.
Zhou X, Zhou L, Yao Z, Huang M, Gong Y, Zou B, Zhu J, Liu Y, Peng F, Zhang Y, Yu M, Li Y, Na F, Wu Y, Kang K, Xiu W, Zhang X, Zhou L, Xu Y, Wang J, Wang Y, Yang X, Wu Y, Li R, Zhang Y, Yang Z, Zhou Z, Bai J, Yi X, Tong R, Yin L, Chen C, Niedermann G, Lu Y, Xue J. Zhou X, et al. Among authors: na f. Clin Cancer Res. 2023 Oct 13;29(20):4098-4108. doi: 10.1158/1078-0432.CCR-23-0315. Clin Cancer Res. 2023. PMID: 37581611
Tff2 defines transit-amplifying pancreatic acinar progenitors that lack regenerative potential and are protective against Kras-driven carcinogenesis.
Jiang Z, Wu F, Laise P, Takayuki T, Na F, Kim W, Kobayashi H, Chang W, Takahashi R, Valenti G, Sunagawa M, White RA, Macchini M, Renz BW, Middelhoff M, Hayakawa Y, Dubeykovskaya ZA, Tan X, Chu TH, Nagar K, Tailor Y, Belin BR, Anand A, Asfaha S, Finlayson MO, Iuga AC, Califano A, Wang TC. Jiang Z, et al. Among authors: na f. Cell Stem Cell. 2023 Aug 3;30(8):1091-1109.e7. doi: 10.1016/j.stem.2023.07.002. Cell Stem Cell. 2023. PMID: 37541213
Fludarabine-Based Low-Intensity Conditioning for Fanconi Anemia is Associated with Good Outcomes in Aplastic Anemia but not in MDS - a Single-Center Experience.
Chattopadhyay S, Lionel S, Selvarajan S, Devasia AJ, Korula A, Kulkarni U, Na F, Sindhuvi E, Lakshmi KM, Srivastava A, Abraham A, Mathews V, George B. Chattopadhyay S, et al. Among authors: na f. Mediterr J Hematol Infect Dis. 2023 Jul 1;15(1):e2023039. doi: 10.4084/MJHID.2023.039. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 37435039 Free PMC article.
70 results